Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.
Jong-Chan Youn, Eui-Soon Kim, Tae Ho Park, Young Soo Lee, Soon Jun Hong, Jin-Yong Hwang, Jung-Kyu Han, Jung-Woo Son, Chan Joo Lee, Jung Hyun Choi, Sung Uk Kwon, Seok Yeon Kim, Hwan-Cheol Park, Seung-Hyuk Choi
Drug Des Devel Ther 20 587488
摘要
摘要
PURPOSE: This 8-week, randomized, double-blind study evaluated the efficacy and safety of low-dose combination of telmisartan 20 mg/S-amlodipine 2.5 mg (T20/SA2.5) versus telmisartan 40 mg (T40) monotherapy in patients with essential hypertension inadequately controlled on T20. PATIENTS AND METHODS: After a 4-week run-in period with T20 (baseline), patients with uncontrolled blood pressure (BP) were randomized (1:1) to T20/SA2.5 or T40 for 8 weeks. The primary endpoint was the change in mean sitting systolic blood pressure (MSSBP) from baseline to week 8. Secondary endpoints included changes in MSSBP and mean sitting diastolic blood pressure (MSDBP) at weeks 4 and 8, BP control rate, response rate (≥20 mmHg reduction in MSSBP and ≥10 mmHg in MSDBP), and treatment-emergent adverse events (TEAEs). RESULTS: Overall, 108 patients were randomized. At week 8, least squares (LS) mean (standard error [SE]) reduction in MSSBP from baseline was greater with T20/SA2.5 than with T40 (-16.97 [2.06] mmHg vs. -7.42 [2.04] mmHg; P<0.001). LS mean (SE) reductions in MSDBP at week 8 were also greater with T20/SA2.5 than with T40 (-7.98 [1.17] mmHg vs. -4.01 [1.15] mmHg; P=0.006). The BP control rate was significantly higher with T20/SA2.5 than with T40 (53.70% vs. 29.63%; P=0.010); the response rate was numerically higher with T20/SA2.5 (12.96% vs. 5.56%; P=0.182). The incidence of TEAEs was lower with T20/SA2.5 than with T40 (9.26% vs. 20.37%, P=0.104); most events were mild. CONCLUSION: T20/SA2.5 demonstrated superior BP-lowering efficacy and favorable tolerability compared with T40 in patients inadequately controlled on T20, supporting the value of early low-dose combination therapy.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(7,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。